Literature DB >> 18570292

Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey.

Donald B Bailey1, Melissa Raspa, Murrey Olmsted, David B Holiday.   

Abstract

Parents enrolling in a national survey of families of children with fragile X (FX) reported whether each of their children had been diagnosed or treated for developmental delay or eight conditions frequently associated with FX: attention problems, hyperactivity, aggressiveness, self-injury, autism, seizures, anxiety, or depression. This article reports results for 976 full mutation males, 259 full mutation females, 57 premutation males, and 199 premutation females. Co-occurring conditions were frequently reported for all FMR1 gene variations. The number of co-occurring conditions experienced was strongly associated with parent reports of their child's ability to learn, adaptability, and quality of life. Most individuals with the full mutation experienced multiple co-occurring conditions, with a modal number of 4 for males and 2 for females. Most (>80%) full mutation males and females had been diagnosed or treated for attention problems. Premutation males, when compared with a matched group of non-FX males, were more likely to have been diagnosed or treated for developmental delay, attention problems, aggression, seizures, autism, and anxiety. Premutation females were more likely to have been diagnosed or treated for attention problems, anxiety, depression, and developmental delay. Clusters of conditions were identified, seeming to occur in an additive fashion. Self-injury, autism, and seizures rarely occurred in isolation, but were more likely in individuals who also had problems with attention, anxiety, and hyperactivity. The findings provide a reference point for future studies on the prevalence and nature of co-occurring conditions in FX; suggest the possibility that certain conditions cluster together; provide evidence that male and female carriers experience elevated rates of co-occurring conditions compared with matched groups of non-carrier children; and emphasize the importance of including an assessment of co-occurring conditions in any clinical evaluation of individuals with abnormal variation in the FMR1 gene. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570292     DOI: 10.1002/ajmg.a.32439

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  202 in total

1.  Daily health symptoms of mothers of adolescents and adults with fragile x syndrome and mothers of adolescents and adults with autism spectrum disorder.

Authors:  Leann E Smith; Marsha Mailick Seltzer; Jan S Greenberg
Journal:  J Autism Dev Disord       Date:  2012-09

2.  Differential sensitivity to life stress in FMR1 premutation carrier mothers of children with fragile X syndrome.

Authors:  Marsha Mailick Seltzer; Erin T Barker; Jan S Greenberg; Jinkuk Hong; Christopher Coe; David Almeida
Journal:  Health Psychol       Date:  2011-12-12       Impact factor: 4.267

Review 3.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Aripiprazole in autism spectrum disorders and fragile X syndrome.

Authors:  Craig A Erickson; Kimberly A Stigler; David J Posey; Christopher J McDougle
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

5.  Infant Temperament in the FMR1 Premutation and Fragile X Syndrome.

Authors:  Bridgette L Tonnsen; Anne C Wheeler; Lisa R Hamrick; Jane E Roberts
Journal:  J Clin Child Adolesc Psychol       Date:  2018-11-05

6.  "If He Has it, We Know What to Do": Parent Perspectives on Familial Risk for Autism Spectrum Disorder.

Authors:  Katherine E MacDuffie; Lauren Turner-Brown; Annette M Estes; Benjamin S Wilfond; Stephen R Dager; Juhi Pandey; Lonnie Zwaigenbaum; Kelly N Botteron; John R Pruett; Joseph Piven; Holly L Peay
Journal:  J Pediatr Psychol       Date:  2020-03-01

7.  Trajectories and predictors of the development of very young boys with fragile X syndrome.

Authors:  Jane E Roberts; Jean B Mankowski; John Sideris; Barbara Davis Goldman; Deborah D Hatton; Penny L Mirrett; Grace T Baranek; J Steven Reznick; Anna C J Long; Donald B Bailey
Journal:  J Pediatr Psychol       Date:  2008-12-12

8.  Biobehavioral indicators of social fear in young children with fragile X syndrome.

Authors:  Bridgette L Tonnsen; Svetlana V Shinkareva; Sara C Deal; Deborah D Hatton; Jane E Roberts
Journal:  Am J Intellect Dev Disabil       Date:  2013-11

9.  Metformin as targeted treatment in fragile X syndrome.

Authors:  A B C Dy; F Tassone; M Eldeeb; M J Salcedo-Arellano; N Tartaglia; R Hagerman
Journal:  Clin Genet       Date:  2017-09-25       Impact factor: 4.438

10.  Fragile X screening: attitudes of genetic health professionals.

Authors:  Kruti Acharya; Lainie Friedman Ross
Journal:  Am J Med Genet A       Date:  2009-02-15       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.